Altre lingue OptiNose, Inc.

Azioni

OPTN

US68404V1008

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 31/05/2024			Variaz. 5gg	Var. 1 gen.
1,08 ^USD	+0,93%		-2,70%	-16,28%

14/05	Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024
14/05	OptiNose, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
OptiNose, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05
OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024	09/05
OptiNose, Inc. Provides Revenue Guidance for the First Quarter of 2024	25/04
Transcript : OptiNose, Inc. - Special Call	25/04
OptiNose, Inc. Provides Earnings Guidance for the Full Year 2025	25/04
OPTINOSE, INC. : Lake Street reste à l'achat	18/03
Sector Update: Health Care Stocks Steady Premarket Monday	18/03
OptiNose, Inc. Announces U.S. Food and Drug Administration Approved XHANCE (Fluticasone Propionate) Nasal Spray for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps in Patients 18 Years of Age and Older	15/03
Optinose, Inc. Provides Update on Hikma Manufacturing Agreement	14/03
OPTINOSE, INC. : HC Wainwright persiste à l'achat	11/03
Transcript : OptiNose, Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
OptiNose, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
OptiNose, Inc. Provides Earnings Guidance for the First Quarter of 2024	07/03
OptiNose, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology	18/01
OptiNose Says US FDA Extended Review of Supplemental New Drug Application for Xhance in Chronic Rhinosinusitis	06/12
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE	06/12
Transcript : OptiNose, Inc., Q3 2023 Earnings Call, Nov 09, 2023	09/11
OptiNose, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue OptiNose, Inc.

Azioni

OPTN

US68404V1008

Altre lingue

Filtri